Dr Reddy's launches immuno-oncology drug Toripalimab in India for treating nasopharyngeal carcinoma

economictimes.indiatimes.com:

Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma in India. Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the upper part of the throat.
The company has launched Toripalimab, a new biological entity (NBE), Dr Reddy's Laboratories said in a regulatory filing.
The medication is the only immuno-oncology drug approved by various regulatory authorities around the world such as the US Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), it added.

Dr Reddy's said it will market the drug under the brand name Zytorvi in India.
«As the next generation PD-1 inhibitor, Toripalimab has demonstrated superior outcomes for RM-NPC versus standard of care, thereby meeting a significant unmet need for patients with NPC in India,» Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said.

• Finance

  Financial Literacy for Non-Finance Executives

  By — CA Raja, Chartered Accountant | Financial Management Educator | Former AVP — Credit, SBI

• Web Development

  C++ Fundamentals for Absolute Beginners

  By — Metla Sudha Sekhar, IT Specialist and Developer

• Marketing

  Modern Marketing Masterclass by Seth Godin

  By — Seth Godin, Former dot com Business Executive and Best Selling Author

• Web